Neoadjuvant GTX Chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer

Journal of Surgical Oncology

Volumn 104, Issue 2, 2011, Pages 155-161

  Patel, Manish ^a   Hoffe, Sarah ^a   Malafa, Mokenge ^a   Hodul, Pamela ^a   Klapman, Jason ^a   Centeno, Barbara ^a   Kim, Jongphil ^a   Helm, James ^a   Valone, Tiffany ^a   Springett, Gregory ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

borderline resectable; chemotherapy; GTX; neoadjuvant; pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; DOCETAXEL; FLUOROURACIL; GEMCITABINE;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; ENDOSCOPIC ECHOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MUCOSA INFLAMMATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS SURGERY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CA-19-9 ANTIGEN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 79959928329     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21954     Document Type: Article

References (24)

1. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet 2004; 363: 1049-1057. (Pubitemid 38410779)
2. Mehta VK, Fisher G, Ford JA, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 2001; 5: 27-35. (Pubitemid 33651235)
3. Warshaw AL, Gu Z-Y, Whittenberg J, et al. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 1990; 125: 230-233. (Pubitemid 20060650)
4. Millikan KW, Deziel DJ, Silverstein JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999; 65: 618-623.
5. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 2001; 5: 121-130. (Pubitemid 33652049)
6. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234: 758-768. (Pubitemid 33117196)
7. Hoffman JP, Weese JL, Solin LJ, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 1995; 169: 71-78.
8. Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group Study. J Clin Oncol 1998; 16: 317-323. (Pubitemid 28041615)
9. Snady H, Bruckner H, Cooperman A, et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma: An outcomes trial. Cancer 2000; 89: 314-327. (Pubitemid 30489879)
10. Wilkowski R, Thoma M, Schauer R, et al. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 2004; 28: 1011-1018. (Pubitemid 40109886)
11. Safran H, Dipetrillo T, Iannitti D, et al. Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: A phase I trial. Int J Radiat Oncol Biol Phys 2002; 54: 137-141.
12. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007; 110: 47-55. (Pubitemid 46986417)
13. Fogelman DR, Schreibman S, Sherman W, et al. Neoadjuvant GTX and radiation for unresectable pancreatic cancer: A prospective phase II trial. In: Proceedings from the 4th Annual Gastrointestinal Cancers Symposium. January 19-21, 2007; Orlando, FL. Abstract 143.
14. Fine RL, Fogelman DR, Schreibman SM, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: A retrospective analysis. Cancer Chemother Pharmacol 2008; 61: 167-175. (Pubitemid 47512638)
15. Landry J, Catalano PJ, Staley C, et al. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 2010; 101: 587-592.
16. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655. (Pubitemid 13149996)
17. Farma JM, Santillan AA, Melis M, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 2008; 15: 2465-2471.
18. National Comprehensive Cancer Network, (NCCN). Practice Guidelines for Pancreatic Cancer. Available at:. Accessed June 1, 2010.
19. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035-1046. (Pubitemid 44337962)
20. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. Am Stat Assoc 1958; 53: 457-481.
21. Gillen S, Schuster T, Meyer zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7: e1000267.
22. Jessup JM, Steele G, Mayer RJ, et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 1993; 128: 559-564. (Pubitemid 23143221)
23. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002; 52: 1293-1302. (Pubitemid 34302881)
24. Crane CH, Ellis LM, Abbruzzese JL, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006; 24: 1145-1151. (Pubitemid 46638812)